又一个中国BIC分子走向了全球。近日,EGFR-TKI阿美替尼在英国获批上市,成为翰森第一款在海外获批的自研新药,也是首个中国原研三代EGFR-TKI在欧洲获批上市,这是翰森创新成果国际化布局的关键落子和里程碑时刻。近些年,诸多国产原创新药出海的“高光时刻”共同构筑起了中国创新药国际化的伟大征程。接力Biotech公司之后,阿美替尼成为第一个由中国Pharma企业原研在欧洲市场上市的创新药品,既...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.